Ohr Pharmaceutical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://ohrpharmaceutical.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
1 (20.0%)Phase 3
1 (20.0%)Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
Phase 3
- Conditions
- Age-related Macular Degeneration
- Interventions
- Drug: Placebo Ophthalmic solution
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT02727881
- Locations
- 🇺🇸
Investigational Site, Madison, Wisconsin, United States
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Phase 1
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02614937
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
Phase 2
Withdrawn
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Registration Number
- NCT02511613
- Locations
- 🇺🇸
Investigational Site, Houston, Texas, United States
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Drug: Vehicle control
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT01678963
- Locations
- 🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸California Retinal Consultants, Bakersfield, California, United States
🇺🇸Retina-Vitreous Associates, Beverly Hilss, California, United States
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
Phase 2
- Conditions
- AnorexiaCancer Cachexia
- Interventions
- Drug: OHR/AVR118
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01206335
- Locations
- 🇨🇦
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
News
No news found